Our Core Technology

Revolutionizing Neurodegeneration Treatment
Through Protein-Based Cell-Free Therapeutics

Dashboard mockup

Technology Overview

A New Era of Neurorepair Innovation
Darwin Cell Biotech pioneers a new class of protein therapeutics derived from stressed mesenchymal stem cells (PDSSCs), offering a multi-target, cell-free solution for CNS disorders. Our proprietary platforms enable safe, scalable, and effective treatments where traditional stem cell or gene therapies fall short.

Our Technology Platforms

Powerful, self-serve product and growth analytics to help you convert, engage, and retain more users. Trusted by over 4,000 startups.

PDSSCs Stress-Induction Platform

Precision induction of therapeutic proteins from MSCs under defined stress conditions.

Functional Protein Screening Platform

Discovery and isolation of high-value bioactive proteins with neuroregenerative properties.

Neurological Disorder Screening Platform

Rapid drug screening using brain organoids, model organisms, and AI-assisted profiling.

IIT Clinical Acceleration Platform

Enabling real-world validation of efficacy in ALS, stroke, AD, and beyond through strategic investigator-initiated trials.

Why Our Technology Leads

Discover how Aleeto outperforms conventional therapies by addressing the core limitations of neurological treatment — with superior safety, multi-target efficacy, and scalable manufacturing.
Traditional Therapies
Low BBB penetration
Exosome/Cell Therapies
Immunogenic risk
Aleeto (PDSSCs Protein Drug)
✅ Human-derived & immune-safe
Single-target effects
Difficult quality control
✅ Multi-pathway synergistic action
High cost & logistics
Batch instability
✅ Stable, scalable production